Authors: | Roberts, K.; Morin, R.; Zhang, J.; Hirst, M.; Zhao, Y.; Su, X.; Chen, S. C.; Payne-Turner, D.; Churchman, M. L.; Harvey, R.; Chen, X.; Kasap, C.; Yan, C.; Becksfort, J.; Finney, R.; Teachey, D.; Maude, S.; Tse, K.; Moore, R.; Jones, S.; Mungall, K.; Birol, I.; Edmonson, M.; Hu, Y.; Buetow, K.; Chen, I. M.; Carroll, W.; Wei, L.; Ma, J.; Kleppe, M.; Levine, R.; Garcia-Manero, G.; Larsen, E.; Shah, N.; Devidas, M.; Reaman, G.; Smith, M.; Paugh, S.; Evans, W.; Grupp, S.; Jeha, S.; Pui, C. H.; Gerhard, D.; Downing, J.; Willman, C.; Loh, M.; Hunger, S. P.; Marra, M.; Mullighan, C. G. |
Article Title: | Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia |
Abstract: | Genomic profiling has identified a subtype of high-risk B-progenitor acute lymphoblastic leukemia (B-ALL) with alteration of IKZF1, a gene expression profile similar to BCR-ABL1-positive ALL and poor outcome (Ph-like ALL). The genetic alterations that activate kinase signaling in Ph-like ALL are poorly understood. We performed transcriptome and whole genome sequencing on 15 cases of Ph-like ALL and identified rearrangements involving ABL1, JAK2, PDGFRB, CRLF2, and EPOR, activating mutations of IL7R and FLT3, and deletion of SH2B3, which encodes the JAK2-negative regulator LNK. Importantly, several of these alterations induce transformation that is attenuated with tyrosine kinase inhibitors, suggesting the treatment outcome of these patients may be improved with targeted therapy. © 2012 Elsevier Inc. |
Journal Title: | Cancer Cell |
Volume: | 22 |
Issue: | 2 |
ISSN: | 1535-6108 |
Publisher: | Cell Press |
Date Published: | 2012-08-14 |
Start Page: | 153 |
End Page: | 166 |
Language: | English |
DOI: | 10.1016/j.ccr.2012.06.005 |
PROVIDER: | scopus |
PMCID: | PMC3422513 |
PUBMED: | 22897847 |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 4 September 2012" - "CODEN: CCAEC" - "Source: Scopus" |